Main Menu

Risks in Moving Too Quickly, or Slowly, on COVID-19 Vaccine

Richard Manning
December 11, 2020
Read the article here

The Food and Drug Administration advisory committee's December 2020 vote in favor of granting emergency use authorization for a COVID-19 vaccine was greeted with enthusiasm by many people who had eagerly anticipated a vaccine and now envision a sooner and more certain end to the pandemic. However, the rapid advancement of this and other COVID-19 vaccines and therapeutics has also been met with concern that the process has moved too quickly. In “Risks in Moving Too Quickly, or Slowly, on COVID-19 Vaccine,” Partner Richard Manning discusses how this situation is analogous to the type 1 vs. type 2 error distinction that arises in statistical inference.


Jump to Page